期刊文献+

雷诺嗪治疗不稳定型心绞痛患者及对其血清C-反应蛋白水平的影响

Clinical effect of Ranolazine in treatment of unstable angina pectoris and its influence on serum C- reactive protein level
下载PDF
导出
摘要 目的:观察常规治疗基础上加用雷诺嗪治疗不稳定型心绞痛患者的临床疗效及对其血清C-反应蛋白水平的影响。方法:将100例不稳定型心绞痛住院患者随机分为对照组和治疗组。对照组患者给予常规治疗,治疗组患者在常规治疗基础上加用雷诺嗪口服治疗,疗程为10 d。结果:治疗组患者总有效率为94%,对照组为92%,两组患者比较差异无显著性(P>0.05);但治疗组患者的显效率明显高于对照组(P<0.05),血清C-反应蛋白水平与治疗前比显著下降(P<0.05),而对照组则无明显变化(P>0.05)。结论:常规治疗基础上加用雷诺嗪治疗不稳定型心绞痛患者疗效优于单纯常规治疗,并能显著降低C-反应蛋白水平。 Objective: To study the clinical effect of Ranolazine in treatment of unstable angina pectoris (UA) (based on rou-tine therapy) and its influence on serum C-reactive protein level. Methods: 100 cases of UA were divided randomly into control groupand treatment group. The control group was given routine therapy, besides this, the treatment group was added with Ranolazine by oral-ly taking. The course of treatment was 10 days. Results: The total effective rates in treatment group and control group were 94% and92%, and there was no significant difference between the two groups (P〉0. 05); however, the marked effective rate in treatmentgroup was higher than that in control group (P〈0. 05). The serum C-reactive protein concentration in treatment group reduced signifi-cantly compared with that before the treatment (P〈0. 05), while it did not change in control group after the treatment (P〉0. 05).Conclusions: Based on routine therapy, added Ranolazine can more effectively treat unstable angina, and reduce the level of serum C-reactive protein significantly.
出处 《中国民康医学》 2015年第3期28-30,共3页 Medical Journal of Chinese People’s Health
关键词 雷诺嗪 不稳定型心绞痛 C-反应蛋白 Ranolazine Unstable angina pectoris C-reactive protein
  • 相关文献

参考文献8

  • 1Bhandari B,Subramanian L. Ranolazine,apartial fatty acid oxidation inhibitor,its patential benefit in angina and other cardiovascular disorders[J]. Recent Pat Cardiovasc Drug Discov,2007,2(1):35-9.
  • 2苗佩宏,徐江平.新型抗心绞痛药物雷诺嗪的研究进展[J].国外医学(药学分册),2003,30(4):197-200. 被引量:17
  • 3Leong Leea,John Horowitzb, Michel F. Metabolic manipulation inischemic heart disease, a novel approach to treatment [J]. EurHeart J,2004,25:634-641.
  • 4Kennedy JA,Klosoglous AJ,Murphy GA,et a1. Effect of Perhexiline and Oxfenicine on myocardial function and metabolism duringlow-flow ischemia/ reperfusion in the isolated rat heart[J]. J Cardiovasc Phamacol,2000,36(6):794-801.
  • 5Grynberg A. Effectors of fatty acic oxidation reduction:promisingnew anti-ischemic gents[J]. Curr Pharm Des,2005,11(4):489-509.
  • 6Mc Cormack JG,Stanley WC,Wolff AA. Ranolazine:a novel metabolic modulator for treatment of angina[J]. Gen Pharmacol,1998,30(5):639-645.
  • 7Allely MC,Brown CM,Kenny BA,et al. Modulation of alpha l-adrenoceptors in rat left ventricle by ischemia and acyl carnitines;protection by Ranolazine[J]. J Cardiovasc Pharmacol,1993,21(6):869-873.
  • 8Antzelevitch C,Belardinelli L,Zygmunt AC,et al. Electophysiological effects of Ranolazine,a novel antanginal agent with antiarrhythmic properties[J]. Circulation,2004,110(8):904-910.

二级参考文献20

  • 1Schofield RS, Hill JA. The uee of ranolazine in cardiovascular disease[J].Expert Opin Investig Drugs,2002,11(1):117-123
  • 2Wolff AA, Rotmensch HH.Metabolic approaches to the treatment of ischemic heart disease:the clinicians'perspective[J].heart Fail Rev,2002,7(2):187-203
  • 3McCormack JG, Barr RL.Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts[J]. Circulation, 1996, 93(1):135- 142.
  • 4Clarke B, Wyatt KM, McCormack JG.Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism[J]. J Mol Cell Cardiol, 1996, 28(2):341-350.
  • 5Allen TJ,Chapman RA.Effects of ranolazine on L-type calcium channel currents in guinea-pig single wentricular myocytes[J].Br J Pharmacol,1996,118(2):249-254
  • 6Letienne R,Vie B,Puech A,et al.Evidence that ranolazine behaves as a weak β1-and β2-adrenoceptor antagonist in the cat cardiovascular system[J].Naunyn Schmiedebergs Arch Pharmacol,2001,363(4):464-471
  • 7Wang JX,Maruyama K,Murakami M,et al.Antianginal effects of ranolazine in various experimental models of angina[J].Arzneimittelforschung,1999,49(3):193-199
  • 8Sabbah HN,Chandler MP,Mishima T,et al.Ranolazine,a partial fatty acid oxidation(pFOX)inhibitor,improves left ventricular function in dogs with chronic heart failure[J].J Card Fail,2002,8(6):416-422
  • 9Chandler MP,Stanley WC,Morita H,et al.Short-sterm treatment with ranolazine improves mechanical effciency in dogs with chronic heart failure[J].Circ Res,2002,91(4):278-280
  • 10?AMorin D,Hauet T,Spedding M,et al.Mitocbondria as target for antiischemic drugs[J].Adv Drug Deliv Rev,2001,49(1/2):151-174

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部